| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5532241 | ABBVIE | Piperidines and piperazines |
Sep, 2019
(4 years ago) | |
| US7834020 | ABBVIE | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(1 year, 10 months ago) | |
| US8673921 | ABBVIE | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(1 year, 10 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8193195 | ABBVIE | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(1 year, 10 months ago) | |
| US8236804 | ABBVIE | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
Jun, 2022
(1 year, 10 months ago) | |
|
US7834020 (Pediatric) | ABBVIE | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(1 year, 4 months ago) | |
|
US8193195 (Pediatric) | ABBVIE | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(1 year, 4 months ago) | |
|
US8236804 (Pediatric) | ABBVIE | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
Dec, 2022
(1 year, 4 months ago) | |
|
US8673921 (Pediatric) | ABBVIE | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(1 year, 4 months ago) | |
Viibryd is owned by Abbvie.
Viibryd contains Vilazodone Hydrochloride.
Viibryd has a total of 9 drug patents out of which 9 drug patents have expired.
Expired drug patents of Viibryd are:
- US8193195
- US8236804
- US7834020*PED
- US8193195*PED
- US8236804*PED
- US8673921*PED
- US5532241
- US7834020
- US8673921
Viibryd was authorised for market use on 21 January, 2011.
Viibryd is available in tablet;oral dosage forms.
Viibryd can be used as treatment of major depressive disorder (mdd).
Drug patent challenges can be filed against Viibryd from 31 July, 2022.
The generics of Viibryd are possible to be released after 31 July, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-146) | Mar 16, 2018 |
| M(M-254) | Jan 31, 2023 |
| Pediatric Exclusivity(PED) | Jul 31, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2016 |
Drugs and Companies using VILAZODONE HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2022
Market Authorisation Date: 21 January, 2011
Treatment: Treatment of major depressive disorder (mdd)
Dosage: TABLET;ORAL
VIIBRYD family patents
